clock menu more-arrow no yes

Filed under:

NPS, Enzon file statement with SEC over their merger

Salt Lake-based NPS Pharmaceuticals Inc. and New Jersey-based Enzon Pharmaceuticals Inc. on Monday said they have filed a registration statement with the U.S. Securities and Exchange Commission regarding their merger.

The statement was filed in the name of Momentum Merger Corp., a newly formed corporation to effect the merger. Momentum's name will be changed before the merger is complete.

After the SEC reviews the registration statement, the joint proxy statement/prospectus will be sent to stockholders of both companies in connection with the companies' special stockholders meetings to approve the merger.

NPS and Enzon announced their $1.6 billion "merger of equals" last month.

NPS stock was up 11 cents at $16.78 per share in early trading Tuesday on Nasdaq. The share price has ranged from $11.59 to $35.35 in the last year.